Completed Clinical Trials
3) A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
4) EISAI E7080- Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine Refractory Unresectable Differentiated Thyroid Cancer Stratified by Histology.
8) A Randomized, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
9) A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study to Assess the Efficacy and Safety of Vandetanib (Caprelsa) 300 mg in Patients with Differentiated Thyroid Cancer that is Either Locally Advanced or Metastatic